Drug

Memantine

Approved · EMA

Emerging researchLate-stage developmentRising momentum

Also known as Donepezil-Memantine, Namenda, Namenda XR, Namzaric+8 more

Donepezil-Memantine, Namenda, Namenda XR, Namzaric, Memantina, 1,3-Dimethyl-5-adamantanamine, 1-Amino-3,5-dimethyladamantane, 3,5-Dimethyl-1-adamantanamine, 3,5-Dimethyl-1-aminoadamantane, 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine, Memantine Hydrochloride, Memantinum.

RxNorm6719 ChEMBLCHEMBL807 ATCN06DX01UNIIW8O17SJF3T

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Clinical trial2026-06-25Results expected Q2 2027 · ClinicalTrials.gov

Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer

Clinical trial2026-06-24Primary completion · ClinicalTrials.gov

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Clinical trial2026-06-09Results expected Q2 2027 · ClinicalTrials.gov

Market withdrawal: Memantine LEK (EMA)

Regulatory2024-09-06EMA

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.

Research2023-07-03Molecular neurodegeneration

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.

Research2022-07-31Neurology and therapy

Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.

Research2022-01-01The Lancet. Neurology

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Research2020-02-14Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Approval: Memantine Accord (EMA)

Regulatory2013-12-03EMA

Approval: Nemdatine (EMA)

Regulatory2013-04-22EMA

Approval: Memantine Mylan (EMA)

Regulatory2013-04-21EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Memantine

Aliases & brands

Donepezil-MemantineNamendaNamenda XRNamzaricMemantina1,3-Dimethyl-5-adamantanamine1-Amino-3,5-dimethyladamantane3,5-Dimethyl-1-adamantanamine3,5-Dimethyl-1-aminoadamantane3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amineMemantine HydrochlorideMemantinum

RxNorm CUI

6719

ChEMBL ID

CHEMBL807

ATC codes

N06DX01

UNII

W8O17SJF3T

Regulatory jurisdictions

ema

Regulatory timeline

7 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2002-05-15

Latest approval

2013-12-03

Authorities

EMA

Total events

emaEuropean Medicines Agency· 7 events

2024-09-06Market withdrawalMarket

Market withdrawal: Memantine LEK (EMA)

Indication: Treatment of patients with moderate to severe Alzheimer’s disease.

Evidence ↗

2013-12-03Approval

Approval: Memantine Accord (EMA)

Indication: Treatment of patients with moderate to severe Alzheimer’s disease.

Evidence ↗

2013-04-22Approval

Approval: Nemdatine (EMA)

Indication: Treatment of patients with moderate to severe Alzheimer’s disease.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

190 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

190

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

119

Late-stage (III+)

120

Completed

Discontinued

PHASE DISTRIBUTIONn = 190

Early Phase 14Phase 114Phase 1 / 25Phase 248Phase 2 / 314Phase 334Phase 450Phase N / A21

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

CompletedPH IVUniversity of California, San Diegon=532025

COMPARATIVE STUDY TO EVALUATE SATISFACTION WITH THE USE OF ORODISPERSIBLE MEMANTINE TABLETS VERSUS CONVENTIONAL TABLETS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: A PHASE IV, RANDOMIZED, OPEN-LABEL STUDY.

CompletedPH IVCarnot Laboratoriesn=1052025

Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

Unknown statusPH IVFirst Affiliated Hospital Xi'an Jiaotong Universityn=1502024

Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)

CompletedPH IVZealand University Hospitaln=1322023

Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies

CompletedPH IVKenneth Myers, MDn=302022

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

CompletedPH IIVanderbilt University Medical Centern=1112026

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

CompletedPH IVUniversity of California, San Diegon=532025

Autonomic Neuromodulation With Ultrasound-Guided Stellate Ganglion Block in Alzheimer's Disease: A Randomized Controlled Trial

CompletedN/ATaizhou Second People's Hospitaln=402025

CompletedPH IVCarnot Laboratoriesn=1052025

Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats: a Multicenter Randomized Double-blind Placebo-controlled Study

CompletedPH IIShanghai East Hospitaln=2562025

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

CompletedPH II/IIIUniversity of California, San Diegon=622025

Research activity

12 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20092023

Most influential

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 605 cites

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

JAMA · 2014 · 380 cites

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.

The Lancet. Neurology · 2013 · 141 cites

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.

Molecular neurodegeneration · 2023 · 103 cites

Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study.

Psychopharmacology · 2010 · 94 cites

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Journal of clinical psychopharmacology · 2009 · 92 cites